Form: 8-K

Current report filing

March 31, 2004

Documents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): March 31, 2004

 

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (804) 648-3820

 

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

 

N/A

 

(b) Pro forma financial information.

 

N/A

 

(c) Exhibits.

 

  99.1 Press Release, dated March 31, 2004, relating to the removal of the “going concern” consideration for Commonwealth Biotechnologies, Inc.

 

2

Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Robert B. Harris, Ph.D.
    Robert B. Harris, Ph.D.
    President and Chief Executive Officer

 

Dated: March 31, 2004

 

3

EXHIBIT INDEX

 

Number
  

Description of Exhibit
99.1   Press Release, dated March 31, 2004, relating to the removal of the “going concern” consideration for Commonwealth Biotechnologies, Inc.

 

4